加载中
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
前收盘价
US$0.2799
−US$0.005 · -1.75%
盘中时间采用ET。市场数据可能有所延迟。
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
日内区间
当前US$0.2799
52周区间
当前US$0.2799
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
卖出
估值
22
偏贵
情绪
53
多空交织
风险
50
风险偏高
动量
29
动能减弱
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
IGC Pharma, Inc. operates as a pharmaceutical firm, currently in the clinical development phase, dedicated to pioneering novel treatments for Alzheimer's, a debilitating condition. The company's pipeline includes two experimental drug candidates aimed at this disease: IGC-AD1, which is presently undergoing a Phase 2 clinical study for addressing agitation associated with Alzheimer's-related dementia, and TGR-63, which is still in its preclinical stage. Beyond its therapeutic development efforts, IGC Pharma also explores the application of artificial intelligence (AI) to advance Alzheimer's research. Established on April 29, 2005, by Ram Mukunda, the company maintains its principal office in Potomac, Maryland.
日内区间
当前US$0.2799
52周区间
当前US$0.2799
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2026财年 | 2025财年 | 2024财年 | 2023财年 | 2022财年 |
|---|---|---|---|---|---|
| 营收 | 118.6万 USD | 127.1万 USD | 134.5万 USD | 91.1万 USD | 39.7万 USD |
| 销货成本 | 83.4万 USD | 65.2万 USD | 61.2万 USD | 106.9万 USD | 20.3万 USD |
| 毛利 | 35.2万 USD | 61.9万 USD | 73.3万 USD | −15.8万 USD | 19.4万 USD |
| 研究与开发 | 519.3万 USD | 365.5万 USD | 377.3万 USD | 346.1万 USD | 233万 USD |
| 销售、一般及管理费用 | 536.2万 USD | 441万 USD | 675.8万 USD | 795.2万 USD | 1329.2万 USD |
| 营业费用 | 1055.5万 USD | 806.5万 USD | 1053.1万 USD | 1141.3万 USD | 1562.2万 USD |
| 折旧和摊销 | 5.8万 USD | 61.8万 USD | 63.7万 USD | 65.7万 USD | 65.1万 USD |
| 营业利润 | −1020.3万 USD | −744.6万 USD | −979.8万 USD | −1157.1万 USD | −1542.8万 USD |
| 净利润 | −654.8万 USD | −712.1万 USD | −1300万 USD | −1150.6万 USD | −1501.6万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2013年4月19日 | 1:10 | — | — |
已生效 2013年4月19日
1:10
报告持有此股票敞口的交易所交易基金。
AI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
